| __timestamp | Ligand Pharmaceuticals Incorporated | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 675200000 |
| Thursday, January 1, 2015 | 24378000 | 771800000 |
| Friday, January 1, 2016 | 26621000 | 1205500000 |
| Sunday, January 1, 2017 | 28653000 | 1146500000 |
| Monday, January 1, 2018 | 37734000 | 1125800000 |
| Tuesday, January 1, 2019 | 41884000 | 1166100000 |
| Wednesday, January 1, 2020 | 64435000 | 1175500000 |
| Friday, January 1, 2021 | 57483000 | 1111400000 |
| Saturday, January 1, 2022 | 70062000 | 1210100000 |
| Sunday, January 1, 2023 | 52790000 | 1274600000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, operational efficiency is key to maintaining a competitive edge. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Perrigo Company plc and Ligand Pharmaceuticals Incorporated, from 2014 to 2023.
Perrigo, a global leader in over-the-counter health products, consistently outpaces Ligand in SG&A spending, with expenses peaking at approximately $1.27 billion in 2023. This represents a 47% increase from 2014, reflecting Perrigo's expansive operational strategies. In contrast, Ligand, known for its innovative drug discovery platform, shows a more modest growth in SG&A expenses, peaking at around $70 million in 2022, a threefold increase from 2014.
This disparity highlights differing business models: Perrigo's broad market approach versus Ligand's focused innovation strategy. Understanding these trends is crucial for investors and industry analysts alike.
Comparing SG&A Expenses: GSK plc vs Ligand Pharmaceuticals Incorporated Trends and Insights
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated Trends and Insights
Operational Costs Compared: SG&A Analysis of Lantheus Holdings, Inc. and Ligand Pharmaceuticals Incorporated
Corcept Therapeutics Incorporated and Perrigo Company plc: SG&A Spending Patterns Compared
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Viking Therapeutics, Inc. and Perrigo Company plc: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Breaking Down SG&A Expenses: Ligand Pharmaceuticals Incorporated vs Novavax, Inc.
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.